PFE - Global Cancer Cachexia Market Size is Estimated to Reach USD 4.74 billion by 2031 Growing at a CAGR of 4.7%: Straits Research | Benzinga
New York, United States, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Increasing Prevalence of Cancer Cachexia to Drive the Global Cancer Cachexia Market
According to the International Agency for Research on Cancer-Globocan 2020 report, there will be 19,292,789 new cancer cases and 9,958,133 cancer-related deaths globally in 2020. Globally, it was estimated that there were 50,550,287 occurrences of cancer over five years. The global incidence of new cancer cases is projected to reach 28,887,940 by 2040. Moreover, according to GLOBOCAN 2020, lung cancer accounted for 2,206,771 new cancer cases identified worldwide in 2020. Additionally, 495,773 pancreatic, 604,100 esophagus, 1,414,259 prostate, and 1,148,515 colon cancers were diagnosed worldwide in 2020. As cachexia is frequent among patients with the aforementioned cancer types, there will be a growing demand for cancer cachexia therapies in the coming years. In addition, Cancer Research UK predicts that the number of individuals with cancer will increase in the future. According to the analysis, assuming existing trends in the prevalence of major diseases and population growth continue, there would be 27.5 million new cancer cases annually worldwide by 2040, a 61.7% rise from 2018. Males are projected to see a 67.6% increase in new cancer cases, and females are projected to experience a 55.3% increase. Thus, the rising prevalence of cancer increases the demand for sophisticated treatment medications, driving the expansion of the market under study.
Download Free Sample Report PDF @ https://straitsresearch.com/report/cancer-cachexia-market/request-sample
Development of Effective Therapeutics for the Treatment of Target Disease to Provide Opportunities for theGlobal Cancer Cachexia Market
As cancer cachexia is a multifactorial syndrome recognized by a progressive degeneration of skeletal muscle mass, various research activities and clinical trials are being designed to evaluate multiple parameters, thereby facilitating the development of effective therapeutics for the targeted disease condition over the next several years. In recent years, the role of brown adipose tissue in cachexia has garnered considerable research interest. In addition, because the pathogenesis of cancer cachexia is multifactorial, treatment options should incorporate multiple-target strategies, such as the use of pharmaconutrients with anti-inflammatory properties, such as omega-3 fatty acids (EPA and DHA), treatment with the peptide hormone "Ghrelin," which is actively involved in anabolic and homeostatic functions, and therapeutics developed based on ActRIIB, which is a high-affinity receptor for adenosine receptor Additionally, research activities to develop non-invasive biomarkers to identify tumors likely to induce cachexia and to identify changes in normal tissues that are characteristic of ...